Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system. Patients had histologically proven, unidimensionally measurable malignant melanoma, incurable by standard therapy. Prio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2004-08, Vol.22 (3), p.315-322
Hauptverfasser:	Burdette-Radoux, Susan, Tozer, Richard G, Lohmann, Reinhard C, Quirt, Ian, Ernst, D Scott, Walsh, Wendy, Wainman, Nancy, Colevas, A Dimitrios, Eisenhauer, Elizabeth A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants Adult Aged Anorexia - chemically induced Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer therapies Cell cycle Chemotherapy Creatinine Cyclin-dependent kinases Cyclin-Dependent Kinases - antagonists & inhibitors Diarrhea Diarrhea - chemically induced Disease prevention Fatigue - chemically induced Female Flavonoids - adverse effects Flavonoids - therapeutic use Granulocytes Humans Immunotherapy Infusions, Intravenous Kinases Male Maximum Tolerated Dose Medical prognosis Melanoma Melanoma - drug therapy Melanoma - pathology Metastasis Middle Aged Nausea Neoplasm Metastasis Patients Piperidines - adverse effects Piperidines - therapeutic use Skin cancer Toxicity Treatment Outcome Vomiting - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!